Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Proteasomal degradation of toxic intracellular amyloid-beta protein by nanobody-enabled proximity to ubiquitin ligase

Protambbody

The amyloid-beta (A) protein arises from the sequential proteolytic cleavage of A precursor protein (APP). The accumulation of A oligomers has been regarded as the causal factor of Alzheimers disease (AD). Basal metabolic production of the A peptide is typical in healthy people, and its production rate is normally lower than its rate of clearance...

Funding Programme
Start Date
End Date
Total Funding
€ 269 418
European Countries Involved

Psychosocial fActors Relevant to BrAin DISorders in Europe

PARADISE

The overall prevalence of brain disorders – both neurological and psychiatric – is very high in Europe. Although it is well known that the burden and costs of these disorders are high, there is evidence that the overall, personal, social and economic costs of brain disorders have been underestimated because of the lack of valid and reliable...

Funding Programme
Start Date
End Date
Total Funding
€ 1 675 934
European Countries Involved

REAL-WORLD IMPLEMENTATION, DEPLOYMENT AND VALIDATION OF EARLY DETECTION TOOLS AND LIFESTYLE ENHANCEMENT

AD-RIDDLE

Alzheimer's disease (AD), the main cause of dementia, is one of the major global health challenges of our time. This disabling disorder affects 55 million people worldwide, with costs above $1.3 trillion. With 67 million people at risk for AD dementia (prodromal and preclinical AD) in Europe alone, it is a major unmet public health need, with...

Funding Programme
Start Date
End Date
Total Funding
€ 12 090 250

Regulation of APP Metabolism by ER-Associated Degradation

APPERAD

The pathological Ab peptide that accumulates in senile plaques in Alzheimer’s disease (AD) brains is derived from a precursor protein APP. Although etiology of AD is complex, genetic evidence shows that duplication of the APP gene locus leading to elevated levels of APP protein is sufficient to cause early-onset AD highlighting the importance of...

Funding Programme
Start Date
End Date
Total Funding
€ 75 000
European Countries Involved

Stochastic Communication Inside Cortical Microcolumns

STOICISM

Neurodegeneration, such as Alzheimer’s disease, currently affects 15 million people in the US with a death rate of 29.5% among 65\ years old and produces a cost around 200 billion dollars per annum. These type of pathologies are caused by neuronal communication failures in multi-scales of the cortical microcolumns. Neuroscience has historically...

Funding Programme
Start Date
End Date
Total Funding
€ 202 681
European Countries Involved

Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions

SMASH-HCM

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease (prevalence 1:200 - 1:500), manifested by thickening of cardiac walls, increasing risks of arrhythmia, and sudden cardiac death. HCM affects all ages - it is the leading cause of death among young athletes. Comorbidities due to gene mutations include altered vascular...

Funding Programme
Start Date
End Date
Total Funding
€ 8 546 366
European Countries Involved

Study feasibility and best route to market for telecare solution in Germany and Japan

NASTEX

Navigil has launched a disruptive wearable mobile personal safefy solution into the Finnish market (http://www.navigil.com/products/s1-wearable-telecare-watch-phone/). The solution has been developed using customer requirements from market leading telecare provider (Esperi Care) who is our first customer and from similar entities in the UK. Wearers...

Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

Super-sensitive detection of Alzheimer’s disease biomarkers in plasma by an innovative droplet split-and-stack approach

SensApp

The detection of biomarkers in body fluids is of great importance for disease early diagnosis. The clinical practice uses typically immunoassay methods (e.g. ELISA, Enzyme-Linked Immuno Sorbent Assay, and related techniques) for biomarker determination. Unfortunately, these techniques fail dramatically in a wide variety of cases where the...

Funding Programme
Start Date
End Date
Total Funding
€ 3 287 563
European Countries Involved

Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease

2D-BioPAD

2D-BioPAD is a cost-effective, non-invasive point of care/self-testing tool for the early and accurate prognosis (assistive diagnosis) of Alzheimer's Disease, with special focus on earlier stages such as Subjective or Mild Cognitive Impairment (SCI/MCI).

Funding Programme
Start Date
End Date
Total Funding
€ 5 957 949
European Countries Involved

Synapsing Mental Disorders and Neurodegenerative diseases: Towards more effective diagnosis and management of psychiatric symptoms

SYNAPSING

Disrupted neuronal connectivity and synapse dysfunction can manifest clinically as a range of emotional, behavioural and cognitive symptoms that are common to, and often overlapping in, mental disorders (MDs) such as major depressive disorder, bipolar disorder and schizophrenia and neurodegenerative disorders (NDs) such as Alzheimers disease and...

Funding Programme
Start Date
End Date
Total Funding
€ 6 999 921
European Countries Involved

Synaptic circuit protection in Alzheimers’s disease (AD) and Huntingtion’s disease (HD): BDNF/TrkB and Arc signaling as rescue factors

CircProt

Alzheimer´s (AD) and Huntington´s disease (HD) result from the erroneous communication of neurons at synapses in different brain areas (neocortex, hippocampus, striatum). The protein BDNF regulates synaptic communication under healthy conditions. However, insufficient release of BDNF from neurons and defective BDNF signaling in target neurons...

Funding Programme
Start Date
End Date
European Countries Involved

The Brain Health Toolbox: Facilitating personalized decision-making for effective dementia prevention

Brain Health Toolbox

Preventing dementia and Alzheimer disease (AD) is a global priority. Previous single-intervention failures stress the critical need for a new multimodal preventive approach in these complex multifactorial conditions. The Brain Health Toolbox is designed to create a seamless continuum from accurate dementia prediction to effective prevention by i)...

Funding Programme
Start Date
End Date
Total Funding
€ 1 498 268
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).